利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.033 秒)

    HMG-CoA reductase inhibitors and method
    1.
    发明申请
    HMG-CoA reductase inhibitors and method 有权
    HMG-CoA还原酶抑制剂及方法

    公开(公告)号：US20050085497A1

    公开(公告)日：2005-04-21

    申请号：US10946055

    申请日：2004-09-21

    申请人： Saleem Ahmad ,  Jeffrey Robl ,  Khehyong Ngu

    发明人： Saleem Ahmad ,  Jeffrey Robl ,  Khehyong Ngu

    IPC分类号： A61K31/505 ,  A61K31/506 ,  A61P3/06 ,  C07D213/74 ,  C07D239/42 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D45/02

    CPC分类号： C07D213/74 ,  C04B35/632 ,  C07D239/42 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12

    摘要： Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholsterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis wherein X is N or CR5; and pharmaceutically acceptable salts thereof, wherein R1 to R7 are as defined herein. A method for treating the above diseases employing the above compounds is also provided.

    摘要翻译： 提供具有以下结构的化合物，其为HMG CoA还原酶抑制剂，因此具有抑制胆固醇生物合成，调节血清脂质，例如降低LDL胆固醇和/或增加HDL胆固醇，以及治疗高脂血症，血脂异常，激素替代疗法， 高胆固醇血症，高甘油三酯血症和动脉粥样硬化以及阿尔茨海默病和骨质疏松症，其中X是N或CR 5; 和其药学上可接受的盐，其中R 1至R 7如本文所定义。 还提供了使用上述化合物治疗上述疾病的方法。

    Non-basic melanin concentrating hormone receptor-1 antagonists
    3.
    发明申请
    Non-basic melanin concentrating hormone receptor-1 antagonists 有权

    公开(公告)号：US20070093508A1

    公开(公告)日：2007-04-26

    申请号：US11586147

    申请日：2006-10-25

    申请人： Saleem Ahmad ,  Khehyong Ngu ,  William Washburn

    发明人： Saleem Ahmad ,  Khehyong Ngu ,  William Washburn

    IPC分类号： A61K31/519 ,  C07D498/02

    CPC分类号： C07D495/04

    摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

    Dihydroquinazolinones as 5HT modulators
    6.
    发明申请
    Dihydroquinazolinones as 5HT modulators 有权
    二氢喹唑啉酮作为5HT调节剂

    公开(公告)号：US20060178386A1

    公开(公告)日：2006-08-10

    申请号：US11350997

    申请日：2006-02-09

    申请人： Saleem Ahmad ,  Khehyong Ngu

    发明人： Saleem Ahmad ,  Khehyong Ngu

    IPC分类号： A61K31/519 ,  C07D487/14

    CPC分类号： C07D487/04

    摘要： The present application provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

    摘要翻译： 本申请提供5-羟色胺受体的调节剂，含有这种调节剂的药物组合物和用于治疗与调节血清素受体相关的各种疾病，病症和病症的方法，所述调节剂包括但不限于肥胖，糖尿病， 糖尿病并发症，动脉粥样硬化，葡萄糖耐量异常和血脂异常; 包括但不限于焦虑，抑郁，强迫症，惊恐障碍，精神病，精神分裂症，睡眠障碍，性障碍和社交恐惧症的中枢神经系统疾病; 头痛 偏头痛 和使用这些化合物和组合物的胃肠道疾病。

    Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
    7.
    发明授权
    Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists 有权
    取代的噻吩并[3,2-D]嘧啶作为非碱性黑色素浓缩激素受体-1拮抗剂

    公开(公告)号：US07745447B2

    公开(公告)日：2010-06-29

    申请号：US11586147

    申请日：2006-10-25

    申请人： William N. Washburn ,  Saleem Ahmad ,  Khehyong Ngu

    发明人： William N. Washburn ,  Saleem Ahmad ,  Khehyong Ngu

    IPC分类号： C07D495/04 ,  A61K31/519 ,  A61P25/22 ,  A61P3/04 ,  A61P3/10

    CPC分类号： C07D495/04

    摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

    摘要翻译： 本申请提供化合物，包括根据式I的所有立体异构体，溶剂合物，前药和药学上可接受的形式。另外，本申请提供含有至少一种根据式I的化合物和任选的至少一种另外的治疗剂的药物组合物。 最后，本申请提供了通过施用治疗有效剂量的根据式I的化合物治疗患有MCHR-1调节的疾病或病症例如肥胖，糖尿病，抑郁或焦虑的患者的方法。